biological source
rabbit
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
EP1601Y, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (305R-14)
vial of 0.5 mL concentrate (305R-15)
bottle of 1.0 mL predilute (305R-17)
vial of 1.0 mL concentrate (305R-16)
bottle of 7.0 mL predilute (305R-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200
isotype
IgG
control
mesothelioma, prostate
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic
Gene Information
human ... KRT5(3852)
Analysis Note
 IVD |  IVD |  IVD |  RUO |
General description
Cytokeratin 5 is an intermediate filament protein of 58 kD molecular weight within the cytokeratin family. It is a type II (basic) cytokeratin. Antibodies to this protein identify basal cells of squamous and glandular epithelia, myoepithelia, and mesothelium. Anti-cytokeratin 5 has been useful in the differential diagnosis of metastatic carcinoma in the pleura versus epithelioid mesothelioma. Epithelioid mesotheliomas are strongly positive in almost all cases, but up to 11% of pulmonary adenocarinomas will show focal immunoreactivity. Almost all squamous cell carcinomas, half of transitional carcinomas, and many undifferentiated large cell carcinomas immunostain with anti-CK 5. Anti-CK 5, along with anti-p63, affords a high sensitivity and specificity for squamous differentiation. Myoepithelial cells of the breast, glandular epithelia, and basal cells of the prostate are labeled with anti-CK 5. This antibody, along with anti-CK 14, has found application in identifying basal-like breast carcinoma, a tumor with poor prognosis. Some carcinomas of ovarian origin may display anti-CK 5 positivity.
Other Notes
Cytokeratin 5 Positive Control Slides, Product No. 305S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
A Douglas-Jones et al.
Histopathology, 47(2), 202-208 (2005-07-28)
To investigate agreement on core biopsy diagnosis of papillary breast lesions, which is acknowledged as a difficult area, and to determine the effect of the use of immunohistochemistry (IHC) to assist diagnosis. Haematoxylin and eosin (H&E) sections of 129 core
Catherine L Clarke et al.
The Journal of pathology, 204(2), 147-152 (2004-09-18)
In recent studies, Böcker and colleagues described a population of cells in paraffin wax sections of normal human breast that express cytokeratins (CK) 5/6 without expression of CK8/18 or smooth muscle actin (SMA). They proposed that these represent stem cells
David J Dabbs et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 19(11), 1506-1511 (2006-08-31)
The basal phenotype of breast carcinoma was demonstrated from a study of gene expression profiles, which demonstrated five carcinoma phenotypes with differing immunohistologic profiles and outcomes. The basal phenotype, so-named because of an immunohistologic profile that is similar to myoepithelial
Camilla E Comin et al.
The American journal of surgical pathology, 31(8), 1139-1148 (2007-08-02)
Distinguishing between epithelioid peritoneal mesothelioma and papillary serous carcinomas involving the peritoneum may be very difficult, owing to overlapping morphologic features. Immunohistochemistry may facilitate establishing a correct diagnosis, but, as no single antibody has demonstrated absolute sensitivity and specificity for
Chad A Livasy et al.
Human pathology, 38(2), 197-204 (2007-01-20)
Microarray profiling of invasive breast carcinomas has identified subtypes including luminal A, luminal B, HER2-overexpressing, and basal-like. The poor-prognosis, basal-like tumors have been immunohistochemically characterized as estrogen receptor (ER)-negative, HER2/neu-negative, and cytokeratin 5/6-positive and/or epidermal growth factor receptor (EGFR)-positive. The
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持